# 10/590026 IAP12 Rec'd PCT/PTO 1 8 AUG 2006

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: OIKAWA1

In re Application of: Nobuhiro OIKAWA et al. Conf. No.:

IA No: PCT/JP2005/002923

Art Unit:

IA Filed: February 23, 2005

Examiner:

Appln. No.: Not Yet Assigned

Washington, D.C.

August 18, 2006

For: HETEROARYLPHENYLUREA DERIVATIVE

#### INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the aboveidentified application, and any other application relying on the filing date of the above-identified application or crossreferencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed:
- [X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [ ] B. before the mailing date of a first office action on the merits or before the mailing of a first Office

action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

- [ ] C. after (A) and (B) above, but before final rejection or allowance, and Applicant has made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below):
  - [ ] i. Counsel certifies that, upon information and belief, each item of information listed herein either was
    - (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
    - [ ] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR \$1.56(c) more than three months prior to the filing of this IDS.
  - [ ] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR §1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.
- [ ] D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant states as follows under 37 CFR \$1.97(e) for consideration of this IDS, that, upon information and belief, each item of information listed herein either was
  - [ ] (a) first cited in a communication from a foreign patent office in a counterpart foreign

application not more than three months prior to the filing of this IDS; or

[] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR \$1.56(c) more than three months prior to the filling of this IDS.

Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR \$1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.

- [X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:
- [ ] A. Document(s) \_\_\_\_\_ is/are deemed substantially cumulative to document(s) \_\_\_\_\_, and, in accordance with 37 CFR \$1.98(c), a copy of each of the former document(s) is not enclosed.
- [ ] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications) Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made

### IAP12 Rec'd PCT/PTO 18 AUG 2006

of record in accordance with 37 CFR \$1.98(d). Per 37 CFR \$1.98(d), copies of these documents need not be filed in this application.

- [X] 3. Documents AB, AD and AE are not in the English language. In accordance with 37 CFR \$1.98(a)(3), Applicant states:
  - [X] An English translation of each document AB, AD, and AE (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.
  - [X] For documents AB, AD and AE, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.
  - [X] A concise explanation of the relevance of documents AB, AD and AE is found in the attached International search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).
  - [ ] A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on page(s) \_\_\_\_\_ of the specification.
  - [ ] A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on the attached sheet.

[ ] A concise explanation of the relevance of document(s) is set forth as follows:

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

## 10/590026 IAP12 Rec'd PCT/PT0 1 8 AUG 2006

- [ ] 5. Other information being provided for the examiner's consideration follows:
- 6. In accordance with 37 CFR \$\$1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR \$1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Roger L. Browdy
Registration No. 25,614

## IAP12 Reg'd PCT/PTO 18 AUG 2006

BN/SB/08A/B

#### Complete if Known 0Substitute for form 1449A/PTO Not Yet Assigned Application Number INFORMATION DISCLOSURE Filing Date Even Date Herewith STATEMENT BY APPLICANT Nobuhiro OlKAWA First Named Inventor Group Art Unit (use as many sheets as necessary) Examiner Name Sheet 1 of 1 Attorney Docket Number OIKAWA1

U.S. PATENT DOCUMENTS									
- 5	No.1	Document Number  Number-Kind Code <sup>2 (It known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Examiner Initials*				Applicant of Cited Document					
→	AA	US-2001/011135	08-02-2001	Riedl Bernd et al.					
		us-							
		us-							
		us-							
		US-							
		US-							
		US-							
		us-							
		us-							
		us-							
		US-							
		us-							
		US-							
		us-							
		US-							
.		US-							
		us-							

		FUREIC	ON PATENT DO	DCUMENTS		
		Foreign Patent Number	Publication Date	Name of Patentee or Applicant	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code <sup>3</sup> Number <sup>6</sup> Kind Code <sup>3</sup> (if known)	MM-DD-YYYY	of Cited Decomposi	Where Relevant Passages or Relevant Figures Appear	<b>⊤</b> °
•	AB	JP 2005-50942JP-2003-509427	03-11-2003	Abbott GmbH & Co KG		AB:
	AC	WO 2003/032989	04-24-2003	Boehringer Ingelheim Pharmaceuticals, Inc.		AB:
-	AD	JP 2003-526613	09-09-2003	Bayer Corporation		AB:
	AE	JP 2002-534468	10-15-2002	Bayer Corporation		AB:
-	AF	WO 01/19828 A2	03-22-2001	Basf Aktiengesellschaft		AB:
→.	AG	WO 00/41698 A1	07-20-2000	Bayer Corporation		AB
	_					L
	_					L
	_					
		1				

$\overline{}$			
Examiner	/Craig Ricci/	Date	10/06/2008
Signature	3	Considered	

\* EXAMNER: Initial if reference considered, whether or not classion is in conformance with MPEP 600. Draw line through classion list not in conformance and not considered, include copy of this form with next communication to applicant. \*Applicant's unique classion designation number (optional). \*See kind Codes of USPTO Petant Documents with workstation or market for the contract of the several petant Documents with workstation or MPEP 0010.4.\* \*Einster Clittle on the several end countent, by the two-letter code (VMP) Standard STJ. \*J. Apparece patent document, the indication of the year of the regin of the Emperor must precede the settle number of the patent document. \*Nint of document by the appropriate an accessor on the option of the Communication of VMPO Standard STJ. \*In Proposition. \*Applicant is by place a clock mark here it Employ his inequal promoteion is statistically applicant to place a clock mark here it Employ his inequal promoteion is statistically applicant to place a clock mark here it Employ his inequal promoteion is statistically applicant to place a clock mark here it Employed his inequal promoteion is statistically applicant to place a clock mark here it Employed his inequal promoteion is statistically applicant to place a clock mark here it Employed his inequal promoteion is statistically applicant to place a clock mark here it Employed his inequal promoteion and the community and the place of the place